BioSpace News Archive

When it comes to a novel virus like SARS-CoV2, a certain amount of “rolling with the punches” is required, and governments and global organizations like the World Health Organization are beginning to dismiss certain treatments and devote themselves wholeheartedly to others.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The current pandemic has caused a major decrease in big money investments into mergers and acquisitions. Could company collaborations be the skeleton key needed to drive life sciences?

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Harvard immunology experts comment on studies regarding antibodies in COVID-19 patients diminishing over time.

Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH)

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues ; program updates planned for December 2020 – – Arvinas and Pfizer enter collaboration and supply agreement ; initiation of Phase 1b combination of ARV-471 and Ibrance ® e xpected in the f ourth q uarter of 2020 –

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2020, and provided a corporate update. “We are 28 days from our PDUFA date and we are ready to launch ORLADEYO to bring HA

–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 – - Collaboration with Ultragenyx creates opportunities to develop additional gene therapies for Duchene muscular dystrophy- – Enhanced cash position resulting from Ultragenyx collaboration and fund-raising activity expected to provide financial runway into the second half of 2021 – – Conference call and webcast scheduled for 8:30 AM ET –

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the three and nine months ended September 30, 2020, and provided operational updates.